6 results match your criteria: "RDBP Jaipuria Hospital[Affiliation]"

Atypical Mumps; are We Heading Towards an Outbreak?

Indian J Otolaryngol Head Neck Surg

October 2024

AIIMS, Bhubneshwar, India.

Article Synopsis
  • Mumps is a contagious disease mainly affecting children and young adults, characterized by salivary gland swelling and potential serious complications like SNHL, orchitis, and meningitis.
  • A recent study conducted in five medical centers across India examined 53 patients with acute salivary gland swelling, revealing a bimodal age distribution and significant symptoms such as fever and gland involvement.
  • The findings indicate a concerning trend of mumps affecting older individuals with increased complications post-COVID-19, highlighting issues related to vaccination, immunity, and the potential for outbreaks in the future.
View Article and Find Full Text PDF

Loss/alteration of Smell and taste sensation is common in CoViD-19 infection. We conducted present study to find out the frequency, onset and severity of these lost sensations and their recovery in mild, moderate and severe COVID 19 positive patients in our setup. A questionnaire based study on 574 COVID-19 positive patients admitted in a dedicated COVID hospital between September-November, 2020 were followed up until their sensations recovered completely or maximum for two months.

View Article and Find Full Text PDF

Congenital talipes equinovarus (CTEV), also known as clubfoot, is a complex congenital deformity of the foot that, left untreated, can limit a person's mobility by making it difficult and painful to walk. Worldwide, 80% of children born with clubfoot are in low- and middle-income countries. The management of clubfoot has a long history.

View Article and Find Full Text PDF

Belimumab in Systemic Lupus Erythematosus.

Indian J Dermatol

October 2016

Department of Skin and VD, RUHS College of Medical Sciences and Government RDBP Jaipuria Hospital, Jaipur, Rajasthan, India.

Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus (SLE). It is a fully humanized IgG1γ monoclonal antibody directed against soluble B lymphocyte stimulator (BLyS). It is indicated as an add-on therapy for the treatment of adult patients with active, autoantibody-positive SLE, who are receiving standard therapy.

View Article and Find Full Text PDF